A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer

Backgraound . High-grade serous ovarian carcinoma (HGSOC) is the most common type of cancer. The prevalence BRCA1/2 germline mutations highest in HGSOC. patients with BRCA gene are more likely to respond platinum-based chemotherapy. Clinical trials demonstrate effectiveness PARP inhibitors treatment -associated Re-administration after response chemotherapy demonstrates an increase progression-free survival rates regardless status. it important for understanding development molecular mechanisms resistance platinum drugs and inhibitors, as well developing new strategies tools overcome resistance. Case description This clinical case hereditary cancer efficacy good tolerability inhibitor maintenance therapy following first relapse, re-administration second relapse. short-course re-treatment was accompanied by multidrug overall time 112 months. Conclusion presence genes a promising justification administration inhibitors. relapsed currently being considered possible therapeutic option. deciphering paramount importance chemoresistance, re-sensitization tumor or